Scholarlink

<p>Sarecycline (Seysara<sup>®</sup>) is a narrow-spectrum, third-generation tetracycline-class antibiotic approved in the USA and in China for once-daily oral treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients aged ≥&#xa0;9 years. With demonstrated efficacy in reducing acne symptoms and with low rates of adverse events commonly associated with other systemic tetracyclines, sarecycline is a valuable treatment option in moderate to severe acne vulgaris. The efficacy of sarecycline in treating acne vulgaris was demonstrated in two pivotal phase 3 trials which reported significant reductions in facial inflammatory lesion counts and higher treatment success rates compared with placebo. Sarecycline is also efficacious in reducing truncal acne, based on post-hoc analyses from the pivotal trials. Additionally, patient-reported outcomes demonstrated that sarecycline recipients had reductions in the psychosocial disease burden of acne. Sarecycline is generally well tolerated, with most adverse events being of mild severity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Sarecycline in moderate to severe acne vulgaris: a profile of its use

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月12日

查看全文
  • Kimberley Chen,
  • Matt Shirley

摘要

Sarecycline (Seysara®) is a narrow-spectrum, third-generation tetracycline-class antibiotic approved in the USA and in China for once-daily oral treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients aged ≥ 9 years. With demonstrated efficacy in reducing acne symptoms and with low rates of adverse events commonly associated with other systemic tetracyclines, sarecycline is a valuable treatment option in moderate to severe acne vulgaris. The efficacy of sarecycline in treating acne vulgaris was demonstrated in two pivotal phase 3 trials which reported significant reductions in facial inflammatory lesion counts and higher treatment success rates compared with placebo. Sarecycline is also efficacious in reducing truncal acne, based on post-hoc analyses from the pivotal trials. Additionally, patient-reported outcomes demonstrated that sarecycline recipients had reductions in the psychosocial disease burden of acne. Sarecycline is generally well tolerated, with most adverse events being of mild severity.